Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 764.81B | 736.56B | 692.16B | 611.63B | 550.34B |
Gross Profit | 275.30B | 261.01B | 239.83B | 216.07B | 185.80B |
EBITDA | 187.97B | 171.26B | 154.67B | 144.60B | 123.82B |
Net Income | 93.76B | 79.64B | 76.31B | 71.44B | 52.87B |
Balance Sheet | |||||
Total Assets | 928.50B | 922.77B | 838.22B | 789.65B | 656.54B |
Cash, Cash Equivalents and Short-Term Investments | 168.60B | 173.94B | 143.46B | 129.63B | 163.03B |
Total Debt | 271.02B | 298.54B | 237.74B | 250.42B | 165.59B |
Total Liabilities | 490.54B | 519.75B | 435.82B | 447.17B | 323.33B |
Stockholders Equity | 434.04B | 399.53B | 399.01B | 339.36B | 330.50B |
Cash Flow | |||||
Free Cash Flow | 123.54B | 92.48B | 64.20B | 55.16B | 55.56B |
Operating Cash Flow | 130.20B | 142.28B | 118.90B | 98.14B | 84.59B |
Investing Cash Flow | -47.59B | -53.42B | -61.19B | -130.55B | -20.52B |
Financing Cash Flow | -87.31B | -47.58B | -44.92B | -8.00B | -13.18B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $5.66T | 31.73 | 8.97% | 0.67% | -1.55% | 17.21% | |
74 Outperform | $3.14T | 33.77 | 22.20% | 1.14% | 3.84% | 19.26% | |
74 Outperform | ¥1.37T | 30.49 | 1.62% | 24.10% | 11.27% | ||
73 Outperform | ¥1.08T | 21.59 | 1.51% | 4.13% | 5.66% | ||
65 Neutral | ¥6.05T | 27.21 | 11.70% | 0.85% | -5.48% | -10.98% | |
63 Neutral | $34.72B | 5.19 | -11.20% | 1.67% | 5.59% | -16.73% | |
54 Neutral | ¥5.56T | 39.00 | 7.94% | 0.63% | 6.21% | 6.41% |
Nomura Research Institute reported a 4.1% increase in revenue for the quarter ending June 30, 2025, with significant growth in operating profit and profit before tax. The company anticipates continued growth for the fiscal year ending March 31, 2026, with projected revenue and profit increases, reflecting a strong market position and positive outlook for stakeholders.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.
Nomura Research Institute, Ltd. announced its relationship with Nomura Holdings, Inc., which holds 23% of NRI’s voting rights, establishing NRI as an affiliated company. Despite this affiliation, NRI operates independently without governance influence from Nomura HD, ensuring its business activities and management decisions remain autonomous. The announcement highlights NRI’s commitment to maintaining independence while continuing its collaborative efforts with Nomura HD, impacting stakeholders by reinforcing NRI’s strategic positioning in the market.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.
Nomura Research Institute, Ltd. has announced its decision to amend its Articles of Incorporation to transition from a ‘Company with an Audit & Supervisory Board’ to a ‘Company with an Audit & Supervisory Committee.’ This change, set to be approved at the upcoming Ordinary General Meeting of Shareholders in June 2025, aims to streamline corporate governance by establishing new provisions for the committee and delegating decision-making powers to board members. This strategic move is expected to enhance operational efficiency and strengthen oversight, potentially impacting stakeholders by improving transparency and accountability within the company.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.
Nomura Research Institute announced a dividend payment from retained earnings, with a year-end dividend of ¥34 per share for the fiscal year ending March 31, 2025, reflecting an increase from the previous year. This decision aligns with NRI’s policy to provide stable dividends while aiming to improve capital efficiency and shareholder returns, with plans to increase the consolidated dividend payout ratio to 40% by March 2026.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.